Tectonic Therapeutic, INC Form 4 insider transactions

Tectonic Therapeutic, Inc. CEO Alise Reicin reported a disposition of 859 common shares at $19.81 each to cover tax withholding obligations related to vested restricted stock units.

Phillip B. Donenberg, a Director at Tectonic Therapeutic, Inc., acquired 10,200 stock options with an exercise price of $24.48, set to vest by June 2026.

Tectonic Therapeutic, Inc. Director Stefan Vitorovic was granted 10,200 stock options with an exercise price of $24.48, aligning his interests with the company's long-term performance.

Tectonic Therapeutic, Inc. Director Terrance McGuire was granted 10,200 stock options with an exercise price of $24.48, vesting by June 2026 or earlier under specific conditions.

Praveen P. Tipirneni, a Director at Tectonic Therapeutic, Inc., was granted 10,200 stock options with an exercise price of $24.48, vesting based on specific conditions.

Timothy A. Springer, a Director and 10% Owner of Tectonic Therapeutic, Inc. (TECX), has acquired 10,200 stock options with an exercise price of $24.48, signaling continued alignment with shareholder interests.

Director Timothy Springer reports multiple purchases of Tectonic Therapeutic (TECX) common stock between April 9th and April 11th, 2025, increasing his direct and indirect holdings.

Director Timothy Springer reports purchasing shares of Tectonic Therapeutic, Inc., increasing his direct and indirect holdings.

Director Terrance McGuire reports the acquisition of 500,000 shares of Tectonic Therapeutic, Inc. at $17.10 per share.

Director Timothy Springer reports acquisition of Tectonic Therapeutic shares through a private placement and holdings via an LLC.

Daniel Lochner, CFO of Tectonic Therapeutic, purchased 4,617 shares of common stock in a private placement transaction.

Chief Scientific Officer Peter McNamara reports acquisition of restricted stock units and stock options in Tectonic Therapeutic, Inc.

Chief Business Officer Marc Schwabish reports acquiring and disposing of Tectonic Therapeutic shares and stock options.

Chief Financial Officer Daniel Lochner of Tectonic Therapeutic, Inc. reports the acquisition of restricted stock units and stock options.

Chief Medical Officer Marcella K. Ruddy acquired shares and options in Tectonic Therapeutic, Inc. on February 4, 2025.

Alise Reicin, CEO of Tectonic Therapeutic, reports acquisition of shares and options in the company, including restricted stock units and employee stock options.

Marc Schwabish, Chief Business Officer of Tectonic Therapeutic, exercised stock options to acquire 2,700 shares of common stock at $2.38 per share on January 28, 2025.

Tectonic Therapeutic's Chief Business Officer, Marc Schwabish, exercised stock options to acquire 2,000 shares of common stock at $2.38 per share.

Tectonic Therapeutic's CEO, Alise Reicin, acquired shares and stock options, as detailed in a recent SEC Form 4 filing.

Peter McNamara, Chief Scientific Officer of Tectonic Therapeutic, exercised stock options to acquire 3,500 shares of common stock.

Director Timothy Springer purchased 300,000 shares of Tectonic Therapeutic at $33.59 per share, increasing his direct holdings to 4,096,764 shares.

Director Timothy Springer reports acquiring and disposing of Tectonic Therapeutic shares through a distribution in kind and open market purchases.

Following the merger of AVROBIO and Tectonic, Braden Michael Leonard reports acquiring shares of Tectonic Therapeutic, Inc. due to the merger agreement.

Director Phillip Donenberg of Tectonic Therapeutic, Inc. reports the acquisition of stock options.

Stefan Vitorovic, a director of Tectonic Therapeutic, reports acquiring shares and stock options as a result of the merger between AVROBIO and Tectonic, along with indirect ownership through Vida Ventures LLCs.

Director Praveen P. Tipirneni reports changes in beneficial ownership of Tectonic Therapeutic securities following the merger with AVROBIO, including acquisition and disposal of common stock and stock options.

Director Timothy A. Springer reports acquiring shares and stock options in Tectonic Therapeutic following the merger with AVROBIO, Inc.

Director Terrance McGuire reports acquisition of common stock and stock options in Tectonic Therapeutic following the merger with AVROBIO, reflecting adjustments from the merger agreement.

Marc Schwabish, Chief Business Officer of Tectonic Therapeutic, reports the acquisition of stock options following the merger, as detailed in a Form 4 filing with the SEC.

Chief Medical Officer of Tectonic Therapeutic, Marcella K. Ruddy, reports acquisition of shares and stock options following the merger with AVROBIO, Inc.